Floatz logo

Therapeutic Asset Ratings

9,920 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Psoriasis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Psoriatic Arthritis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Mixed Phenotype Acute Leukemia
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Rheumatoid Arthritis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Sjogren Syndrome
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Mycosis Fungoides And Variants
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Systemic Lupus Erythematosus
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Systemic Sclerosis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Virus Associated Tumor
National Cancer Institute (NCI)P1CC (43)
NK-92
Glioblastoma
Johann Wolfgang Goethe University HospitalP1CC (43)
NKG2D CAR-NK
Metastatic Malignant Neoplasm
Zhejiang UniversityP1CC (43)
nkg2d-car-nk92 cells
Refractory Malignant Neoplasm
Henan Medical UniversityP1CC (43)
nkt3447
Gastric Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
nkt3447
Endometrial Disorder
NiKang Therapeutics, Inc.P1CC (43)
nkt3447
Breast Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
nkt3447
Her2-Receptor Negative Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
nkt3447
Metastatic Neoplasm
NiKang Therapeutics, Inc.P1CC (43)
nkt3447
Progesterone-Receptor Positive Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Gastric Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Endometrial Disorder
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Breast Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Her2-Receptor Negative Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Endometrial Carcinoma
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Metastatic Neoplasm
NiKang Therapeutics, Inc.P1CC (43)
nkt3964
Progesterone-Receptor Positive Breast Cancer
NiKang Therapeutics, Inc.P1CC (43)
Showing 3501 to 3525 of 9,920 assets
PreviousPage 141 of 397Next